证券代码：300109 证券简称：新开源 公告编号：2025-038 博爱新开源医疗科技集团股份有限公司 第五届董事会第十八次会议决议公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）审议并通过《关于 2025 年第三季度报告的议案》 经与会董事认真核查，一致认为：公司编制《2025 年第三季度报告》的程 序符合法律、法规和中国证监会的规定，报告内容真实、准确、完整的反映了公 司的财务状况和经营成果，不存在虚假记载、误导性陈述和重大遗漏。 公司董事会审计委员会已审议通过本议案。 公司监事会对本议案发表了审核意见。 具体内容详见公司于同日在巨潮资讯网上披露的《2025 年第三季度报告》。 表决结果：同意票 9 票；反对票 0 票；弃权票 0 票。 特此公告 博爱新开源医疗科技集团股份有限公司 董事会 2025年10月27日 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届董事会第十八次会议于 2025 年 10 月 26 日下午在公司三楼会议室以现场 加通讯的表决方式召开，本次会议通知已于 2025 年 1 ...

Financial Performance - Q3 2025 revenue was CNY 307,485,118.87, a decrease of 18.26% year-over-year[4] - Net profit attributable to shareholders was CNY 62,131,375.22, down 36.80% compared to the same period last year[4] - Basic earnings per share decreased by 35.00% to CNY 0.13[4] - Total operating revenue for the current period was ¥951,499,451.66, a decrease of 14.3% compared to ¥1,110,998,865.19 in the previous period[23] - Operating profit decreased to ¥246,285,561.67, down 32.5% from ¥365,444,704.90 in the previous period[23] - The total profit for the current period is ¥247,112,754.41, a decrease of 31.5% compared to ¥361,362,351.81 in the previous period[24] - The net profit attributable to shareholders of the parent company is ¥201,088,081.22, down 35.5% from ¥311,243,169.86 year-on-year[24] - The company reported a net profit margin decline, with net profit for the period not specified but indicated by the decrease in operating profit and revenue[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,242,583,261.89, a decrease of 2.96% from the end of the previous year[4] - Total assets decreased to ¥4,242,583,261.89 from ¥4,372,054,795.55, a decline of 3.0%[21] - Total liabilities decreased significantly to ¥552,113,797.56 from ¥764,369,013.92, a reduction of 27.7%[20] - Non-current assets totaled ¥2,694,635,651.16, down from ¥2,860,302,242.49, reflecting a decrease of 5.8%[20] - The company's equity attributable to shareholders increased to ¥3,722,171,012.11 from ¥3,637,934,717.51, an increase of 2.3%[20] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 213,795,586.24, down 24.58%[4] - The net cash flow from operating activities is ¥213,795,586.24, a decline of 24.5% compared to ¥283,480,027.15 in the previous period[26] - The total cash and cash equivalents at the end of the period is ¥452,253,258.50, compared to ¥258,209,827.62 at the end of the previous period, indicating an increase of 75.2%[27] - The cash inflow from operating activities totaled ¥987,024,485.78, slightly down from ¥1,012,192,179.39 in the previous period[26] - The cash outflow from investing activities was ¥241,453,522.90, compared to ¥296,772,529.36 in the previous period, showing a decrease of 18.7%[26] - The net cash flow from financing activities was -¥303,645,420.70, compared to a positive cash flow of ¥9,457,768.10 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,248[11] - The largest shareholder, Wang Donghu, holds 8.66% of shares, totaling 42,095,222 shares, with 31,571,416 shares pledged[11] - The company plans to distribute a cash dividend of 2.493056 RMB per 10 shares, totaling 121,175,001.25 RMB, based on a total share capital of 486,050,005 shares[16] - The top ten shareholders collectively hold a significant portion of the company's equity, with the largest holding being 8.66%[11] - There are no changes in the status of shares for the top ten shareholders due to margin trading activities[12] - The company has no preferred shareholders or changes in restricted shares during the reporting period[13] Research and Development - R&D expenses increased by 33.76% to CNY 55,383,433.26, reflecting higher investment in innovation[10] - Research and development expenses rose to ¥55,383,433.26 from ¥41,403,619.57, marking an increase of 33.7%[23] - The company’s subsidiary has received approval for clinical trials of a new drug targeting advanced solid tumors[16] Other Information - The company reported a significant increase in long-term borrowings by 656.82% to CNY 156,014,509.38, indicating a shift in financing strategy[10] - The company experienced a 49.33% decline in net profit after deducting non-recurring gains and losses, totaling CNY 52,518,461.73[4] - The company has invested a total of 50 million RMB in Huadao (Shanghai) Biomedical Co., Ltd., acquiring 12.2150% and 0.7168% equity stakes[17] - The company’s board member Zhao Wei is under investigation for alleged insider trading activities[16] - The company has no new strategies or mergers and acquisitions reported in this period[18]

Group 1 - On October 23, Xin Kai Yuan's stock decreased by 0.73%, with a trading volume of 82.59 million yuan [1] - The financing data shows that on the same day, Xin Kai Yuan had a financing buy-in amount of 11.58 million yuan and a financing repayment of 20.01 million yuan, resulting in a net financing outflow of 8.43 million yuan [1] - As of October 23, the total balance of margin trading for Xin Kai Yuan was 819 million yuan, with the financing balance accounting for 10.30% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010, with its main business involving the research, production, and sales of PVP series products and other high-value-added pharmaceutical excipients [2] - The revenue composition of Xin Kai Yuan includes: PVP Others 39.57%, PVPK30 Powder 28.35%, Oruisi Series 14.80%, PVP-I 6.85%, Precision Medical Services 3.45%, Early Cancer Diagnosis 3.08%, Genetic Testing Technology 3.04%, and Molecular Diagnostic Services 0.87% [2] - For the first half of 2025, Xin Kai Yuan reported an operating income of 644 million yuan, a year-on-year decrease of 12.36%, and a net profit attributable to the parent company of 139 million yuan, down 34.74% year-on-year [2] Group 3 - Since its A-share listing, Xin Kai Yuan has distributed a total of 900 million yuan in dividends, with 607 million yuan distributed over the past three years [3]

Key Points - The low-altitude economy continues to attract significant financing, with capital concentrating on leading companies. Recently, Zero Gravity Aircraft Industry (Hefei) Co., Ltd. announced the completion of A++++ round financing amounting to nearly 300 million yuan, bringing its total financing in two months to nearly 700 million yuan [4][11]. - Quantum computing competition is intensifying, with multiple technological routes being pursued. Logic Bit, a superconducting quantum computing company, completed a Pre-A round financing of tens of millions of yuan, primarily from existing shareholders [4][13]. Additionally, Bosc Quantum completed an A++ round financing of several hundred million yuan [4][15]. - In the health sector, early-stage tools and platform technologies are receiving support. OxTium Technology announced the completion of several million yuan in angel+ round financing led by Sequoia China Seed Fund [5][33]. - The new consumption sector is also seeing active financing, with Velotric completing a B round financing led by Shunwei Capital [8]. - The hard technology sector is witnessing significant investments, with companies like Rock Energy and BridGene Biosciences completing substantial financing rounds [14][36]. - The healthcare industry is experiencing a surge in financing, with companies like Yike Medical and Wuyou Jump completing rounds of several million to nearly 200 million yuan [28][30]. - The AI and enterprise service sectors are also active, with companies like Future Intelligence and Aishi Technology completing significant financing rounds [43][46]. Group 1 - Low-altitude economy financing remains high, with Zero Gravity Aircraft Industry raising nearly 300 million yuan [4][11] - Quantum computing competition is heating up, with Logic Bit and Bosc Quantum securing significant funding [4][13][15] - Health sector tools and platforms are gaining early-stage support, exemplified by OxTium Technology's financing [5][33] Group 2 - New consumption sector financing is active, with Velotric's B round led by Shunwei Capital [8] - Hard technology sector investments are significant, with Rock Energy and BridGene Biosciences completing major financing [14][36] - Healthcare industry financing is surging, with Yike Medical and Wuyou Jump securing substantial rounds [28][30] Group 3 - AI and enterprise service sectors are also seeing significant financing, with Future Intelligence and Aishi Technology completing major rounds [43][46]

Core Viewpoint - The company, Xin Kai Yuan (300109), has projected that by October 10, 2025, the number of its shareholders will reach approximately 20,200 households [1] Summary by Relevant Sections - **Company Information** - Xin Kai Yuan has communicated to investors that it anticipates a total of around 20,200 shareholders by the specified date [1]

Core Insights - Andrej Karpathy has released a new open-source project called nanochat, which allows users to build a ChatGPT-like model from scratch for approximately $100 [2][5] - The project consists of around 8,000 lines of code and was quickly adopted by the community, gaining over 4,500 stars on GitHub within 12 hours [2][5] - nanochat provides a complete training and inference pipeline for large language models (LLMs), differing from Karpathy's previous project, nanoGPT, which only covered the pre-training phase [2][5] Project Details - Users can train their own LLM by running a script on a cloud GPU machine, achieving a functional model in about 4 hours [2][3] - The project includes features such as a new Rust-based tokenizer, a high-efficiency inference engine, and automatic generation of Markdown scorecards summarizing the training process [3][5] - Karpathy estimates that with a budget of $1,000 and 41.6 hours of training, users can achieve significant improvements in model coherence and performance on various tasks [4][5] Performance Metrics - Initial CORE scores for the model were recorded at 0.2219, with improvements noted during different training phases [7] - The model's performance on specific benchmarks includes scores such as 40+ on MMLU and 70+ on ARC-Easy after sufficient training [4][7] Community and Future Development - Karpathy envisions nanochat evolving into a research platform or standard benchmark, similar to nanoGPT, and encourages community collaboration for further improvements [5][8] - Despite its capabilities, Karpathy cautions that nanochat is not suitable for personalized applications without significant additional work and data preparation [9][10]

Core Viewpoint - The company Xin Kai Yuan has experienced fluctuations in stock price and financial performance, with a notable decrease in revenue and net profit in the first half of 2025 compared to the previous year [2]. Group 1: Stock Performance - As of October 9, Xin Kai Yuan's stock price increased by 2.10%, reaching 18.02 CNY per share, with a trading volume of 40.23 million CNY and a turnover rate of 0.50%, resulting in a total market capitalization of 8.76 billion CNY [1]. - Year-to-date, the stock price has risen by 14.77%, but it has seen a decline of 4.10% over the last five trading days and 3.53% over the last twenty days, while increasing by 9.80% over the last sixty days [1]. - The net inflow of main funds was 1.22 million CNY, with significant buying and selling activities recorded [1]. Group 2: Financial Performance - For the first half of 2025, Xin Kai Yuan reported operating revenue of 644 million CNY, a year-on-year decrease of 12.36%, and a net profit attributable to shareholders of 139 million CNY, down 34.74% year-on-year [2]. - The company has distributed a total of 900 million CNY in dividends since its A-share listing, with 607 million CNY distributed over the past three years [3]. Group 3: Business Overview - Xin Kai Yuan, established on March 13, 2003, and listed on August 25, 2010, is located in Jiaozuo City, Henan Province, and specializes in the research, production, and sales of PVP series products, high-value pharmaceutical excipients, and in vitro diagnostic services [1]. - The main business revenue composition includes: PVP Others 39.57%, PVPK30 Powder 28.35%, Oruisi Series 14.80%, PVP-I 6.85%, Precision Medical Services 3.45%, Early Tumor Diagnosis 3.08%, Gene Testing Technology 3.04%, and Molecular Diagnostic Services 0.87% [1].

Investment Rating - The report maintains an "Accumulate" rating for the company [2][6][13] Core Views - The company's Q2 2025 performance showed a decline both year-on-year and quarter-on-quarter, but the PVP application range is extensive, and the medical sector is showing signs of recovery [2][13] - The report projects a decrease in EPS for 2025 and 2026 to 0.70 and 0.82 CNY respectively, with a new EPS estimate for 2027 at 1.02 CNY [13] - The target price is set at 23.10 CNY based on a 33x PE valuation for 2025 [13] Financial Summary - Total revenue for 2023 is projected at 1,583 million CNY, with a slight increase to 1,606 million CNY in 2024, followed by a decrease to 1,520 million CNY in 2025 [4][14] - Net profit attributable to the parent company is expected to decline from 493 million CNY in 2023 to 350 million CNY in 2024, and further to 342 million CNY in 2025 [4][14] - The company’s gross margin and net margin for Q2 2025 were reported at 41.86% and 18.2% respectively, showing a decline from Q1 2025 [13] Market Data - The company's current price is 17.89 CNY, with a 52-week price range of 11.95 to 19.87 CNY [6][7] - The total market capitalization is approximately 8,695 million CNY [7] Industry Insights - PVP is widely used across various sectors including pharmaceuticals, food industry, and electronics, with applications enhancing battery performance and electronic skin sensitivity [13] - The report indicates a stabilization in PVP prices after a significant drop in H1 2025, which had previously impacted revenue and margins [13]

Core Insights - New Kaineng is strategically positioning itself in the biopharmaceutical sector through systematic investments and a dual business model of "fine chemicals + precision medicine" [2][5][8] - The company aims to build a robust technology matrix in biomedicine by investing in high-potential firms and focusing on cutting-edge technologies like CAR-T cell therapy [2][3][4] Investment Strategy - The core logic of New Kaineng's investment decisions is to achieve industrial chain synergy, selecting complementary investment targets that enhance existing business capabilities [3] - The company employs a "diversified portfolio + phased dynamic investment" strategy to balance risk and return, allowing for investments in various technological paths to mitigate R&D risks [3][4] Business Transformation - New Kaineng has transitioned from a focus on PVP in fine chemicals to a dual business model that includes precision medicine, driven by the need to overcome development bottlenecks [5][6] - The company is leveraging historical opportunities in the healthcare service industry by establishing specialized medical service platforms [6] Infrastructure Development - The establishment of the Songjiang base is a key strategic move for New Kaineng, serving as a hub for integrating into the Yangtze River Delta biopharmaceutical ecosystem [7][8] - The Songjiang base is designed to enhance resource aggregation and facilitate efficient collaboration across the biopharmaceutical supply chain, significantly improving operational efficiency [7] Future Outlook - New Kaineng anticipates a concentrated release of investment returns in the coming years, with several drug pipelines entering clinical stages and expected approvals within 3 to 5 years [4] - The company aims to create a biopharmaceutical industry matrix that emphasizes technological collaboration and resource sharing, rather than mere diversification [8]

Core Viewpoint - The company New Open Source (300109.SZ) aims to enhance its competitive advantage in the precision medicine sector through a strategic investment in Huada Bio and its shareholders [1] Investment Details - New Open Source and its subsidiary Wuhan He'er Medical Technology Development Co., Ltd. plan to sign an investment agreement with Huada Bio and its 28 shareholders [1] - The company will invest a total of RMB 30 million and RMB 20 million in Huada Bio through capital increase, resulting in ownership stakes of 12.2150% and 0.7168% respectively [1]